Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19279271 | Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient Opening | July 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19177721 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | April 2025 | September 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 19063141 | NOVEL COMPOUNDS | February 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19001374 | Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient Opening | December 2024 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18847377 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | September 2024 | February 2026 | Abandon | 17 | 1 | 1 | No | No |
| 18672696 | PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOF | May 2024 | January 2026 | Abandon | 20 | 3 | 1 | No | No |
| 18635765 | LOW-SORBING GLYBURIDE FORMULATION AND METHODS | April 2024 | September 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18628560 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | April 2024 | January 2025 | Allow | 9 | 0 | 0 | Yes | No |
| 18614143 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | March 2024 | January 2026 | Allow | 22 | 0 | 0 | Yes | No |
| 18597119 | Preparation method of glufosinate or derivatives thereof | March 2024 | April 2025 | Allow | 14 | 4 | 0 | Yes | Yes |
| 18591965 | HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | February 2024 | March 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18591753 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | February 2024 | September 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18432931 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | February 2024 | September 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18432824 | METHODS AND MATERIALS FOR IMPROVING ARTERIOVENOUS FISTULA MATURATION AND MAINTAINING ARTERIOVENOUS FISTULA FUNCTIONALITY | February 2024 | October 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18420446 | FUSED RING COMPOUND HAVING UREA STRUCTURE | January 2024 | November 2024 | Allow | 10 | 1 | 0 | No | No |
| 18392680 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | December 2023 | April 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18506762 | 5-(3-SUBSTITUTED PHENYL)-PYRIMIDO[4,5-d]PYRIMIDINE-2,4,7(1H,3H,8H)-TRIONE DERIVATIVES AS ANTICANCER AGENTS | November 2023 | February 2024 | Allow | 3 | 1 | 0 | No | No |
| 18495213 | Crystal Form Of Pyrazolyl-Amino-Pyrimidinyl Derivative, And Preparation Method Therefor And Use Thereof | October 2023 | July 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18557458 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | October 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18556896 | CRYSTAL FORM OF THIOPHENE DERIVATIVE AND PREPARATION METHOD THEREFOR | October 2023 | March 2026 | Allow | 29 | 1 | 0 | Yes | No |
| 18483311 | GLP-1 Receptor Agonists and Uses Thereof | October 2023 | March 2025 | Allow | 18 | 1 | 0 | No | No |
| 18285285 | Long lasting Opioid Reversal Using Hydrogen Peroxide-Induced Release in Blood | October 2023 | January 2026 | Allow | 27 | 0 | 0 | Yes | No |
| 18476131 | METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS | September 2023 | July 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18469995 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | September 2023 | March 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18462780 | TRICYANOHEXANE PURIFICATION METHODS | September 2023 | June 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 18448150 | A LYOPHILIZED PHARMACEUTICAL COMPOSITION | August 2023 | November 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18263481 | ANTIVIRAL AGENTS AND USES THEREOF | July 2023 | December 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18225859 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | July 2023 | November 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18346342 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof | July 2023 | March 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18334385 | SULFAMATE MODULATORS OF PIN1 ACTIVITY AND USES THEREOF | June 2023 | February 2026 | Allow | 32 | 0 | 1 | Yes | No |
| 18265422 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | June 2023 | February 2024 | Allow | 8 | 1 | 0 | No | No |
| 18327647 | cGAS INHIBITORS | June 2023 | October 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18038802 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | May 2023 | October 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18318760 | RIPK1 INHIBITORS AND METHODS OF USE | May 2023 | September 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18315267 | IRAK DEGRADERS AND USES THEREOF | May 2023 | April 2024 | Abandon | 11 | 0 | 1 | No | No |
| 18137281 | 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODH | April 2023 | July 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18249762 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | April 2023 | October 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18136765 | POLYMORPHISMS OF HM30181 MESYLATE | April 2023 | November 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 18134735 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | April 2023 | September 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 18134894 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | April 2023 | August 2023 | Allow | 4 | 0 | 1 | Yes | No |
| 18134747 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | April 2023 | May 2024 | Allow | 13 | 4 | 0 | Yes | No |
| 18247139 | HSD17B13 INHIBITORS AND USES THEREOF | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18126765 | PYRIDO[3,4-b]INDOL-1-ONE COMPOUNDS AS ANTIBACTERIAL AGENTS | March 2023 | August 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18187487 | METHODS OF TREATING OPHTHALMIC CONDITIONS WITH ENHANCED PENETRATION COMPOSITIONS OF BIMATOPROST AND TIMOLOL | March 2023 | May 2025 | Abandon | 26 | 4 | 0 | No | No |
| 18041719 | 1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | February 2023 | September 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18011499 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | December 2022 | September 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 18000945 | ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMOD | December 2022 | March 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 18008399 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | December 2022 | November 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17923899 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17967273 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES | October 2022 | April 2025 | Allow | 29 | 0 | 1 | Yes | No |
| 17967342 | INHIBITORS OF AV ß6 INTEGRIN | October 2022 | November 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17955730 | COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS | September 2022 | October 2025 | Allow | 36 | 2 | 0 | Yes | No |
| 17906946 | BUCCAL AND ENTERIC DELIVERY OF FATTY ACIDS IN FOODS AND BEVERAGES | September 2022 | May 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17822494 | COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISEASES, COMPRISING CHLORPROMAZINE | August 2022 | July 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17799950 | PRAMIPEXOLE HYDROCHLORIDE ORAL LIQUID | August 2022 | March 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 17785646 | ANTHELMINTIC COMPOUNDS COMPRISING AZAINDOLES STRUCTURE | June 2022 | July 2025 | Allow | 37 | 1 | 0 | No | No |
| 17840532 | SYNERGISTIC COMPOSITION FOR ACTIVATING INTRACELLULAR SECONDARY MESSENGER(CAMP) PATHWAY | June 2022 | December 2024 | Allow | 31 | 7 | 0 | Yes | No |
| 17831469 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | June 2022 | September 2023 | Allow | 16 | 1 | 0 | No | No |
| 17752609 | COMBINATION THERAPIES | May 2022 | August 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17741356 | VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH A CYP3A INHIBITOR AND AZACITIDINE | May 2022 | January 2026 | Abandon | 44 | 4 | 0 | No | No |
| 17735011 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | May 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17727125 | COMPOUNDS FOR TREATING PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) MEDIATED DISEASES OR CONDITIONS | April 2022 | September 2023 | Abandon | 17 | 0 | 1 | No | No |
| 17659558 | PHARMACOLOGICAL TREATMENT OF AUTISM SPECTRUM DISORDER | April 2022 | March 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17714298 | HETEROCYCLIC RED AZO COLORANTS FOR SEED TREATMENT APPLICATIONS | April 2022 | February 2025 | Allow | 35 | 1 | 1 | No | No |
| 17710050 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | March 2022 | January 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17707297 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | March 2022 | May 2023 | Allow | 13 | 0 | 0 | Yes | No |
| 17705155 | PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | March 2022 | November 2025 | Allow | 44 | 1 | 0 | No | No |
| 17689969 | Intraarterial (IA) Application of Low Dose of Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Impermeable Therapeutics Brain Entry | March 2022 | June 2025 | Allow | 40 | 5 | 1 | Yes | No |
| 17683470 | COMBINATION THERAPY USING A MALT1 INHIBITOR AND A BTK INHIBITOR | March 2022 | July 2024 | Abandon | 29 | 2 | 0 | Yes | No |
| 17638341 | CRYSTALLINE FORMS OF A CD73 INHIBITOR | February 2022 | June 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17637426 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | February 2022 | September 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17636634 | PROCESS FOR THE PREPARATION OF APALUTAMIDE | February 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17635421 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | February 2022 | March 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17650555 | ANALGESIC FORMULATION FOR PERINEAL PAIN | February 2022 | September 2023 | Abandon | 19 | 1 | 1 | No | No |
| 17667519 | Neurologist Formulated Nocturnal Nootropic Founded on a Novel Theory of Brain Aging | February 2022 | October 2025 | Abandon | 45 | 0 | 1 | Yes | No |
| 17587565 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | January 2022 | February 2025 | Allow | 37 | 4 | 1 | No | No |
| 17629899 | COCRYSTALS OF POSACONAZOLE, METHODS OF MAKING AND USING SAME | January 2022 | June 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17582728 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | January 2022 | April 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17624970 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | January 2022 | March 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17597165 | IRAK DEGRADERS AND USES THEREOF | December 2021 | July 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17616614 | IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASES | December 2021 | July 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17615337 | MONTELUKAST SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | November 2021 | August 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17615437 | METHOD FOR SYNTHESIZING FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHIC SUBSTANCE AND POLYMORPHIC SUBSTANCE OF SALT | November 2021 | March 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17614921 | LIQUID COMPOSITION COMPRISING MEFENTRIFLUCONAZOLE | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17613239 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | November 2021 | September 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17513448 | POLYMORPHISMS OF HM30181 MESYLATE | October 2021 | March 2023 | Allow | 17 | 0 | 0 | Yes | No |
| 17513284 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | October 2021 | March 2023 | Allow | 17 | 0 | 0 | Yes | No |
| 17439638 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | September 2021 | March 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17427269 | INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17288982 | Combination Therapies For Treating Cancer | April 2021 | November 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 17288742 | COMPOSITIONS AND METHODS FOR TREATING GOUT AND HYPERURICEMIA | April 2021 | August 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17283646 | MST1 KINASE INHIBITOR AND USE THEREOF | April 2021 | February 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17283754 | METHODS FOR TREATING OR PREVENTING SKIN CONDITIONS | April 2021 | December 2025 | Abandon | 57 | 2 | 1 | No | No |
| 17283724 | MALONATE SALT OF VARLITINIB | April 2021 | August 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17283151 | TYK2 KINASE INHIBITORS | April 2021 | August 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17282277 | COVALENT TARGETING OF E3 LIGASES | April 2021 | June 2024 | Allow | 39 | 0 | 1 | Yes | No |
| 17215959 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | March 2021 | October 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17280628 | CONDENSED-CYCLIC COMPOUND | March 2021 | July 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17213362 | CINNOLINE COMPOUNDS AND USES THEREOF | March 2021 | December 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17280211 | Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases | March 2021 | February 2025 | Abandon | 47 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIM, DAVID M..
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SHIM, DAVID M. works in Art Unit 1626 and has examined 62 patent applications in our dataset. With an allowance rate of 58.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner SHIM, DAVID M.'s allowance rate of 58.1% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHIM, DAVID M. receive 1.23 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SHIM, DAVID M. is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +83.2% benefit to allowance rate for applications examined by SHIM, DAVID M.. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.6% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 7.7% of cases where such amendments are filed. This entry rate is in the 8% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.